Target intelligence / Profile preview

Trifunctional purine biosynthetic protein adenosine-3 (GART) (GART)

Target
GART
Molecular classification
Enzyme
01

Overview

Trifunctional purine biosynthetic protein adenosine-3 (GART) is a multi-domain, trifunctional enzyme that plays a pivotal role in the de novo purine nucleotide biosynthetic pathway. It catalyzes three non-sequential steps in this pathway: phosphoribosylamine-glycine ligase (GARS), phosphoribosylformylglycinamidine cyclo-ligase (AIRS), and phosphoribosylglycinamide formyltransferase (GART/GARFT). Because rapidly proliferating cancer cells exhibit a high demand for purine nucleotides to support DNA replication and RNA transcription, GART is frequently overexpressed in various malignancies, including breast cancer, lung cancer, glioma, and colorectal cancer. Consequently, GART has emerged as an attractive therapeutic target in oncology. Antifolate drugs, such as the approved agent pemetrexed and investigational inhibitors like lometrexol, pelitrexol (AG2037), and LY309887, target the formyltransferase domain of GART to disrupt purine synthesis, deplete cellular ATP/GTP pools, and induce cell cycle arrest and apoptosis. However, clinical development of selective GART inhibitors has historically been challenged by cumulative toxicities, such as myelosuppression and mucositis, which are often managed with folate supplementation.

Other names
GARS-AIRS-GARTGlycinamide ribonucleotide transformylaseGlycinamide ribonucleotide synthetase-aminoimidazole ribonucleotide synthetase-glycinamide ribonucleotide transformylasePhosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetasePGFTPRGSGARSAIRSGARTFPAISPhosphoribosylamine--glycine ligasePhosphoribosylformylglycinamidine cyclo-ligasePhosphoribosylglycinamide formyltransferase
02

Mechanism of action

Enzyme inhibition, antimetabolite activity, and disruption of de novo purine nucleotide biosynthesis

03

Biological functions

Cell cycleApoptosisCell proliferationOther
04

Disease associations

CancerInflammationOther
05

Safety considerations

Delayed cumulative toxicityMyelosuppressionAnemiaThrombocytopeniaMucositisDiarrheaHyperbilirubinemiaFatigue
06

Interacting drugs

8 more in the full profile.

07

Biomarkers

GART mRNA expressionGART protein expressionIntracellular ATP depletionFolate receptor alpha expressionFolylpolyglutamate synthetase activityReduced folate carrier expression

Beyond the preview

Go deeper on Trifunctional purine biosynthetic protein adenosine-3 (GART) (GART).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Trifunctional purine biosynthetic protein adenosine-3 (GART) (GART).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call